Clinical Trial Update: Alphanate in Immune Tolerance Induction Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for Alphanate in immune tolerance induction therapy was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hemophilia
• Hemophilia

Drugs mentioned

• Alphanate (antihemophilic factor VIII concentrate)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Hemophilia A, Congenital | Phase 2 | Status: TERMINATED | Results posted: 2021-11-23